1. Medtech Insight

Podcast: Thermo Fisher Talks Regulatory Experience With Oncomine

US FDA recently approved Oncomine Dx Target Test, the first multi-drug next-generation sequencing test made by Thermo Fisher Scientific. The test is a companion diagnostic for lung-cancer drugs made by Novartis and Pfizer, and the diagnostic company is looking to expand its partnership to other pharma companies.

Laboratory
Thermo Fisher's Oncomine Dx Target Test is the first multi-drug next-generation sequencing test approved by US FDA • Source: Thermo Fisher Scientific

Thermo Fisher Scientific Inc. announced last month it received US FDA approval of its Oncomine Dx Target Test, the first next-generation sequencing test approved for multiple drugs. Because of the uniqueness of the test and regulatory path it took, Medtech Insight spoke to Joydeep Goswami, president of the Clinical Sequencing Division in the firm's Life Sciences Group, to learn more.

Oncomine was developed by Thermo Fisher and used by the National Institutes of Health to study various forms of non-small...

More from Regulation

New EU Rules Limit Chinese Participation In Medtech Procurement

 
• By Amanda Maxwell

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

Guidance Details EU Approach On Medtech, AI Regulation Interplay

 
• By Amanda Maxwell

Overlapping clinical testing requirements and decision-making around significant changes to MDAI are among the tricky subjects that the new document explains.

UK MHRA Joins New Global Network For Safe Use Of AI In Healthcare

 
• By Natasha Barrow

The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.

More from Policy & Regulation